Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of xaliproden to prevent oxaliplatin-induced neurotoxicity in first-line metastatic colorectal cancer
2005-002570-30Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic colon cancer (mCRC) comparing Xaliproden arm with Placebo arm (2 arms). Primary endpoint: Grade 3–4 peripheral sensory neuropathy probability. Started Sep 2005; status: completed.
02
Drugs
xaliproden
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2005-002570-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002570-30.